Alice Epitropoulos, MD, on How Xiidra, TrueTear, and Other Treatments Impact Practices, Patients

Tune in to the latest episode of the Eye On Innovation podcast where Carey Powers dives into the dynamic world of biotech investor pitch decks with special guest Dr. Rob Rothman, Founding Partner of InFocus Capital Partners. Discover the top five mistakes to avoid when crafting your pitch deck and gain exclusive insights from Dr. Rothman's wealth of experience in ophthalmology and venture capital.

In this episode, you'll learn:

• The importance of tailoring your pitch deck to specific investors.
• Strategies for keeping your pitch deck concise and engaging.
• Why it's crucial to address challenges, competition, and reimbursement in your presentation.
• The art of storytelling and its impact on investor engagement.

Don't miss out on this enlightening discussion—subscribe to the OIS podcast today and stay ahead of the curve in biotech innovation!

Join us this week on the OIS podcast as host Carey Powers sits down with Dr. Paul Karpecki to explore the latest advancements in presbyopia treatment strategies. Here's what you can expect from this insightful conversation:

• Insider Insights: Dr. Karpecki shares insider insights gleaned from his extensive clinical experience and research in the field of presbyopia treatment.
• Financial Potential: Discover the potential for unprecedented financial gains in the rapidly evolving market of presbyopia treatment.
• Cutting-Edge Strategies: Uncover the latest cutting-edge strategies and developments in the treatment of presbyopia, offering hope and solutions to millions affected by this common eye condition.

Tune in to this episode for an in-depth look at the future of presbyopia treatment and the exciting opportunities it presents!

In the latest episode of the OIS Podcast, host Dr. Robert Rothman engages in a captivating dialogue with Dr. Prasad Sunkara, CEO of Eyegenex.

Key points discussed in the episode:

• Prasad's multifaceted background spanning agricultural sciences to pharmaceuticals.
• Eyegenex's pioneering work in gene and peptide therapies for ophthalmic conditions.
• The personal journey and insights driving Prasad's commitment to advancing ophthalmology.

For a deep dive into this thought-provoking conversation, tune in to the OIS Podcast and explore the forefront of ophthalmic innovation.

 This panel discussion on startup commercial strategy explores key elements and insights from industry leaders, Paul Bresge, Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, offering a comprehensive view of the journey from regulatory approval to commercialization. Beth Marsh, Lead of Sales and Marketing at Apellis, sets the stage by emphasizing the importance of early consideration of commercial strategy.
 Key topics covered in the discussion include:

• Early Commercial Strategy
• Elements of Robust Strategy
• Raising Institutional Funding
• Evolution of Strategies
• Future Anticipation

Don't miss out – listen now for a comprehensive view of navigating the complexities of startup success!

OIS Podcast host Carey Powers speaks with Dr. Adrienne Graves and Dr. Barbara Wirostko on 'Maximizing the Value of Your Board of Director' live from OIS XIII.

Dr. Graves and Dr. Wirostko share valuable insights on:
* Building effective boards
* Significance of diversity
* CEO and board member communications
* Navigating decision-making
* Board dynamics
* Strategic collaboration

This episode is a must-listen for CEOs and founders navigating the intricacies of leadership and strategic decision-making. Tune in now.

In this episode of the OIS Podcast, host Dr. Firas Rahhal, along with expert panelists, Dr. Robert Bhisitkul, Dr. Alan Franklin and Dr. Paul Karpecki at OIS XIII, takes listeners on a deep dive into the transformative landscape of oral therapies in retina treatment, challenging the conventional approach dominated by eye injections. Tune in as they explore the groundbreaking realm of oral treatments and shed light on their novelty in retinal care.

The discussions are comprehensive, covering key aspects such as:

•  Novelty in Retina Treatment
•  Three-Step Improvement and Long-Term Vision Protection
•  Optimism for Prevention and Early Intervention
•  Clinical Trial Parameters and Market Potential
•  Diverse Mechanisms in Focus

Don't miss out on this enlightening episode that explores the dynamic landscape of oral therapies, offering a fresh perspective on their potential to revolutionize the field of ophthalmology. Stay informed and engaged with OIS XIII discussions, as experts discuss the exciting possibilities that oral therapies bring to the forefront of retinal treatment.

ViaLase, a clinical stage medical technology company located in Aliso Viejo, CA is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care.

With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase is now bringing that expertise and innovation to glaucoma patients.

In this episode, Chief Commercialization Officer, Shawn O’Neil chats with OIS host Dr. Rob Rothman and discusses his successful product launches and instrumental contributions to ViaLase's commercialization strategy, their unique reimbursement strategy, the treatment's durability over time, enhancing its long-term impact, and much more.

Tune in and see how ViaLase plans to bring this revolutionary treatment to glaucoma patients across the globe.

Resources
ViaLase: https://www.vialase.com
Sean O’Neil: LinkedIn
Robert Rothman, MD ois.net/robert-rothman-md

Opthea, an Australian based biopharmaceutical company is dedicated to transforming retinal disease treatments and elevating patients' vision and quality of life. Join Firas Rahal, MD, in a captivating episode as he engages with Opthea's Founder and Chief Innovation Officer, Megan Baldwin, PhD.

Explore the compelling journey from oncology to ophthalmology, unraveling strategic decisions, navigating competitive landscapes, and achieving triumphs in clinical trials. Dr. Baldwin unfolds her remarkable career trajectory, from a PhD at the University of Melbourne to pivotal roles at Genentech and the Ludwig Institute for Cancer Research.

Tune in for exclusive insights, including:

• Opthea's strategic approach to revolutionizing eye care
• Clinical Trials: A deep dive into their success and impact
• Comparison with Other Drugs: Differentiating factors and unique contributions
• Future Directions: Exploring new horizons and clinical opportunities
• Commercialization Timeline: Anticipated milestones and FDA approval strategies

Listen now for a compelling journey through Opthea's vision as they continue to shape the landscape of ophthalmological advancements.

Opthea: Opthea.com
Megan Baldwin, PhD: LinkedIn
Firas Rahal, MD ois.net/robert-rothman-md

Harrow isn’t a household name (yet), but eye care professionals have trusted its products for over a decade.

The Nashville-based company produces Dexycu, an intraocular steroid; Iopidine for intraocular pressure control; and most recently, five Novartis products that Harrow acquired in December 2022.

Rob Rothman, MD, caught up with Harrow founder and CEO Mark Baum to find out how he grew the company from worse than nothing—he acquired, restructured, and reorganized a company in bankruptcy in 2011—to a publicly traded organization with an enterprise value of $750 million.

Baum describes Harrow as a “consortium of entrepreneurs.” That consortium includes:

• Eton Pharmaceuticals, developing products to treat rare disease
• Surface Ophthalmics, developing preservative-free products to treat dry eye disease and post-operative pain
• Melt Pharmaceuticals, which produces MKO Melt, an FDA-approved analgesic

Harrow built its business off compounded medications. By meeting needs of physicians in that way, it grew from zero to over 10,000 customers in a relatively short time.

Looking ahead, Baum wants to build Harrow’s portfolio and its brand recognition, all while abiding by the company’s mission: to give patients access to affordable ophthalmic medications.

Listen to the podcast today to discover:

• More about Baum’s career path, including his background as a lawyer and investor, his move into business, and the event that prompted him to reorganize and restructure what is now Harrow.
• Harrow’s corporate philosophy and why Baum considers the company a consortium of entrepreneurs.
• How Harrow grew from zero to over 10,000 customers in a few years.
• The secret to Harrow’s success, including how it profits from smaller, but no less important, assets.
• What’s next for Harrow, including the upcoming launch of Vevye, a dry eye drop based on Novaliq’s proprietary EyeSol water-free technology.
• How Harrow plans to grow within the next five years, and whether that includes developing its own products.

Resources

Harrow:                       harrow.com

Mark Baum:                marklbaum.com and on LinkedIn

Rob Rothman, MD      ois.net/robert-rothman-md